Senti Biosciences Holdings, Inc.

What they do

Senti develops next-generation cell and gene therapies using its gene circuit platform and Regulator Dial technology. Its pipeline includes CAR-NK cell therapies for oncology, a controllable gene therapy for Rett Syndrome, and armored tumor-infiltrating lymphocytes (TILs) for solid tumors. The company is transitioning to focus on Regulator-Dial-powered controllable genetic medicines.

Revenue drivers

• Contingent Value Right (CVR) from SENTI-202 spin-off — Up to $60 million in milestone payments over seven years from NewCo, including $10M on BLA filing, $20M on FDA approval, and $30M on $200M cumulative net sales.
• Research collaborations and grants — Historically generated small collaboration revenues (e.g., $2.3M in 2021, $3.3M in 2022, $2.0M in 2023), but no revenue in 2024; 2025 revenue was $22,000.
• Regulator Dial platform licensing — Potential future licensing or partnership deals for the Regulator Dial platform, though no specific agreements have been disclosed.

Recent performance

For Q1 2026, Senti reported a net loss of $4.2 million and used $7.5 million in operating cash, down from a $14.1 million net loss in Q1 2025. As of March 31, 2026, cash and equivalents were $8.9 million, down from $16.4 million at year-end 2025. Accumulated deficit reached $362.8 million. Full-year 2025 net loss was $61.4 million on revenue of $22,000, with operating cash burn of $43.4 million.

Strategy

Management is executing a strategic pivot: spinning off the Gene-Circuit pipeline (including SENTI-202) into a private NewCo controlled by Celadon affiliates, distributing a CVR to shareholders, and retaining the Regulator Dial platform for next-generation controllable genetic medicines. The company plans to seek additional financing to advance early-stage programs for Rett Syndrome and armored TILs for solid tumors. Senti will use its synthetic biology and AI expertise to optimize Regulator-Dial-powered therapies.

Risks

• CVR milestone dependence — Future shareholder value from the spin-off is tied to SENTI-202's BLA filing, FDA approval, and $200 million cumulative sales, all uncertain and years away.
• Cash runway and financing need — With only $8.9 million in cash and ongoing losses, the company requires additional financing to fund operations and retained programs.
• Early-stage pipeline execution — Retained programs (Rett Syndrome gene therapy, armored TILs) are early-stage and may fail to meet clinical or regulatory endpoints.
• Spin-off and shareholder approval — The transaction is subject to shareholder approval and customary closing conditions, and may not close as planned.

Outlook

Management expects operating losses to increase as it expands research on the Regulator Dial platform and seeks financing. The company will focus on controllable cell and gene therapies, with near-term milestones tied to the spin-off closing and early-stage program advancement. SENTI-202 development will continue under NewCo, with potential CVR payments if milestones are met.